Heterogeneity in benign and malignant salivary gland tumors

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-03-19 DOI:10.1016/j.cca.2025.120258

Mehdi Ghasemian , Mohammad Amin Gholami , Mohammad Javad Fattahi , Farnia Ghasemi , Hamid Ghaderi , Bijan Khademi , Abbas Ghaderi , Mohammad Reza Haghshenas

{"title":"Heterogeneity in benign and malignant salivary gland tumors","authors":"Mehdi Ghasemian , Mohammad Amin Gholami , Mohammad Javad Fattahi , Farnia Ghasemi , Hamid Ghaderi , Bijan Khademi , Abbas Ghaderi , Mohammad Reza Haghshenas","doi":"10.1016/j.cca.2025.120258","DOIUrl":null,"url":null,"abstract":"<div><div>Advanced proteomics tools have identified the role of proteins in cancer biology, highlighting the importance of these molecules for biomarker discovery and providing valuable insights into cancer diagnosis, prognosis, and targeted therapy. Proteome analysis of tissue using high-throughput proteomics techniques has identified proteins associated with recurrence and malignant transformation in benign tumors, and protein profiling of fine needle aspiration has revealed potential biomarkers for distinguishing malignant salivary gland tumors from benign ones. In addition, proteomics studies have identified distinct protein expression patterns in mesenchymal stem cells derived from malignant salivary gland tumors, suggesting a potential role for proteins in adverse behavior and/or targeted therapy. To provide a comprehensive knowledge of salivary gland tumors, this review will first provide a brief description of the molecular and cellular alterations in common benign and malignant salivary gland tumors and then describe the proteomics studies by concentration on different biological sources including serum/plasma, saliva, tumor tissues and related derivatives (e.g. mesenchymal stem cells, tumor cells, tumor established cell lines, and fine needle aspiration), and introduce potential targets for diagnosis, prognosis, and cancer therapy.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"572 ","pages":"Article 120258"},"PeriodicalIF":3.2000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125001378","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Advanced proteomics tools have identified the role of proteins in cancer biology, highlighting the importance of these molecules for biomarker discovery and providing valuable insights into cancer diagnosis, prognosis, and targeted therapy. Proteome analysis of tissue using high-throughput proteomics techniques has identified proteins associated with recurrence and malignant transformation in benign tumors, and protein profiling of fine needle aspiration has revealed potential biomarkers for distinguishing malignant salivary gland tumors from benign ones. In addition, proteomics studies have identified distinct protein expression patterns in mesenchymal stem cells derived from malignant salivary gland tumors, suggesting a potential role for proteins in adverse behavior and/or targeted therapy. To provide a comprehensive knowledge of salivary gland tumors, this review will first provide a brief description of the molecular and cellular alterations in common benign and malignant salivary gland tumors and then describe the proteomics studies by concentration on different biological sources including serum/plasma, saliva, tumor tissues and related derivatives (e.g. mesenchymal stem cells, tumor cells, tumor established cell lines, and fine needle aspiration), and introduce potential targets for diagnosis, prognosis, and cancer therapy.

Abstract Image

查看原文本刊更多论文

良性和恶性涎腺肿瘤的异质性。

先进的蛋白质组学工具确定了蛋白质在癌症生物学中的作用，突出了这些分子对生物标记物发现的重要性，并为癌症诊断、预后和靶向治疗提供了宝贵的见解。利用高通量蛋白质组学技术对组织进行蛋白质组分析，发现了与良性肿瘤复发和恶性转化相关的蛋白质，而对细针穿刺的蛋白质分析则揭示了区分恶性唾液腺肿瘤和良性肿瘤的潜在生物标记物。此外，蛋白质组学研究还发现了恶性涎腺肿瘤间充质干细胞中不同的蛋白质表达模式，这表明蛋白质在不良行为和/或靶向治疗中可能发挥作用。为了提供有关涎腺肿瘤的全面知识，本综述将首先简要介绍常见良性和恶性涎腺肿瘤的分子和细胞改变，然后集中介绍不同生物来源的蛋白质组学研究，包括血清/血浆、唾液、肿瘤组织和相关衍生物（如间充质干细胞、肿瘤细胞、肿瘤建立的细胞系和细针穿刺），并介绍诊断、预后和癌症治疗的潜在靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.